Pfizer adds heft to obesity pipeline in $2B Yaopharma deal
A month after besting rival Novo Nordisk A/S in a bidding war for obesity drug developer Metsera Inc., Pfizer Inc. is again adding to its GLP-1 arsenal, this time via a $2 billion licensing and collaboration agreement with Yaopharma, a subsidiary of China’s Fosun Pharmaceutical Co. Ltd.
Eli Lilly to make GLP-1 pill in US
CNN’s Erin Burnett speaks to Eli Lilly CEO David Ricks on major changes to weight-loss drugs and expanded manufacturing. Watch the full interview on Erin Burnett OutFront. #CNN #News
Breakthrough GLP-1 implant promises major weight-loss benefits for pets
The world’s first GLP-1 weight loss treatment is being administered for pets on an experimental basis. The first cat was successfully dosed in the MEOW-1 study of OKV-119 – an investigational “ultra-long acting” GLP-1 implant, which, according to a press release, is being developed for weight management in cats. OKAVA Pharmaceuticals, the San Francisco-based manufacturer […]
Target beefs up protein, supplement offerings, capitalizing on weight loss drug trend
The rapid adoption of GLP-1 weight loss medications — drugs like Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Zepbound and Mounjaro — is reshaping how Americans eat and shop. It’s also changing how major corporations do business. From new product lines to expanding certain categories, companies are trying to capitalize on the lifestyle shifts […]
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly’s oral GLP-1, orforglipron Company plans to create 3,450 manufacturing and construction jobs at Lilly’s ninth U.S. manufacturing site announced since 2020 INDIANAPOLIS, Dec….
Weight loss drugs fill a gap for women with hormonal disorder PCOS | REUTERS
Many women with PCOS say they struggled for years to get a diagnosis and effective treatment. Now, more are finding relief as GLP-1 prescriptions for PCOS rose over sevenfold in the US since 2021. #pcos #glp1 #novonordisk #elililly #hormonaldisorder #News #Reuters #Newsfeed Read the story here: https://reut.rs/4rGTKhD 👉 Subscribe: http://smarturl.it/reuterssubscribe Keep up with the latest […]
FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes
The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, to reduce the risk of major adverse cardiac events in adults with type 2 diabetes who are at high risk of these conditions.
Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China
YaoPharma’s once-daily oral GLP-1 drug is currently in Phase 1 testing. The license agreement gives Pfizer global rights to the small molecule, which it envisions as part of potential drug combinations. The post Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China appeared first on MedCity News.
Looming GLP-1 drug patent expirations draw generics firms
India and China are among the countries where knockoffs of Wegovy and Ozempic can be sold next year
GLP-1s may not affect obesity-related cancer risk: Study
A new study from researchers at Cambridge, Mass.-based Harvard University found that blockbuster GLP-1 drugs such as Ozempic and Zepbound may have a minimal effect on an individual’s risk of developing obesity-related cancers. The study, published Dec. 9 in Annals of Internal Medicine, is based on a review of 48 randomized controlled trials involving 94,245 […]